RB1 mutation had influenced on bone metastases in advanced treatment-naïve lung cancer.

Authors

null

Chengzhi Zhou

The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China

Chengzhi Zhou , Ying Xu , Xinqing Lin , Fei Wang , Huojin Deng , Xiaohong Xie , Ming Liu , Zhanhong Xie , Jiexia Zhang , Ming Ouyang , Shiyue Li , Rongchang Chen , Yinyin Qin , Rongrong Chen , Xuefeng Xia

Organizations

The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China, Department of Computer Science and Technology, School of Electronic and Information Engineering, Xi’an Jiaotong University, Xi’an, Shaanxi, China, Xi'an, China, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China, Department of Respiratory Medicine, Zhujiang Hospital, Southern MedicaI University, Guangzhou, 510280, China, Guangzhou, China, Guangzhou Institute of Respiratory Health, Guangzhou Medical University the First Affiliated Hospital, Guangzhou, China, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Institute of Respiratory Health, Guangzhou, China, State Key Laboratory of Respiratory Disease, Shunde Hospital Affiliated to Guangzhou Medical University,Guangzhou Institute of the Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China, Geneplus-Beijing Ltd., Beijing, China, Houston Methodist Research Institute, Weill Cornell School of Medicine, Houston, TX

Research Funding

Other Foundation
State Key Laboratory of Respiratory Disease—The Independent Project

Background: RB1 is one of the most vital cancer suppressor genes in various cancer types. RB1 mutation always occurs in treatment-naïve small cell lung cancer (SCLC) patients or in resistance to EGFR TKI therapy of non-small cell lung cancer (NSCLC) patients. However, we observed a group of clinical NSCLC patients, and found that RB1 mutations also occurred in treatment-naïve patients. Methods: RB1 is one of the most vital cancer suppressor genes in various cancer types. RB1 mutation always occurs in treatment-naïve small cell lung cancer (SCLC) patients or in resistance to EGFR TKI therapy of non-small cell lung cancer (NSCLC) patients. However, we observed a group of clinical NSCLC patients, and found that RB1 mutations also occurred in treatment-naïve patients. Results: Nonsense and frame-shift mutations were the major pathogenic mutations found in RB1 gene, which predicted RB1 protein-deficient in these mutational patients. Furthermore, we found these RB1 mutation patients had TP53 mutations at the same time. Patients with RB1 mutation had a higher smoking prevalence than patients who had wildtype RB1 genes (P < 0.0001). Gene testing showed RB1 mutations patients also developed EGFR driver mutations, while the mutation frequency was significantly lower than RB1 wildtype patients (P = 0.0368). Eight RB1 mutated patients diagnosed with actionable EGFR mutations, including exon 19 del, L858R, L861Q, G719S and S768I, while no patients diagnosed with EGFR exon 20 insertion. 10 (62.5%, 10/16) patients in RB1 mutated group, and 25(32.1%, 25/78) patients with RB1 wildtype had bone metastases. The proportion of bone metastases in patients with RB1 mutation was significantly increased than others (P = 0.0216). Conclusions: This study demonstrates that the function of tumor suppressor gene RB1 in advanced stage of NSCLC. From the results, we considered RB1 mutation had influence on bone metastases. Although loss-of-function mutations in tumor suppressor gene (TSG) RB1 always had no targets therapeutic drugs, it also suggested that some other clinically treatment can be performed as soon as possible.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Publication Only

Session Title

Publication Only: Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Citation

J Clin Oncol 38: 2020 (suppl; abstr e21668)

DOI

10.1200/JCO.2020.38.15_suppl.e21668

Abstract #

e21668

Abstract Disclosures